RxDoctor Payments Data

Alma Hernandez

Psychiatric/Mental Health · Springdale, ARNPI 1346997681

Payments from drug & device makers

$1,657in general payments, 2019–2025

Across 66 payments — averaging $25.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$332
  • Alkermes, Inc.$253
  • Johnson & Johnson$238
  • Axsome Therapeutics, Inc.$201
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$155
  • Supernus Pharmaceuticals, Inc.$110
  • plus $367 from 7 others

What the payments were for

  • Food & beverage$1,657100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,657 in reported general payments places this provider in the 65th percentile of 359 psychiatric/mental health providers in Arkansas.

See all psychiatric/mental health providers in Arkansas

Medicare billing

Part B allowed, 2024
$18,164
Medicare patients
53
Services billed
225

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate24$203,739
Invega TrinzaPaliperidone Palmitate15$117,013
Invega SustennaPaliperidone Palmitate33$104,684
AristadaAripiprazole Lauroxil27$85,023
VraylarCariprazine Hcl33$45,276
Abilify MaintenaAripiprazole13$37,319
FanaptIloperidone12$23,358
Paliperidone ErPaliperidone32$10,615
Chlorpromazine Hcl29$6,446
Aripiprazole114$6,166
BelsomraSuvorexant13$5,153
Lurasidone Hcl23$4,139
Clomipramine Hcl14$3,836
Clozapine62$3,799
Oxcarbazepine62$2,262

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Trinza, Invega Sustenna$238$221,69748 claims
Neurocrine Biosciences, Inc.Ingrezza$86$203,73924 claims
Alkermes, Inc.Aristada$253$85,02327 claims
AbbVieVraylar$332$45,27633 claims
Vanda Pharmaceuticals Inc.Fanapt$51$23,35812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 359 psychiatric/mental health providers in Arkansas.

Other psychiatric/mental health in Springdale

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →